Celsion Announces Publication of Findings from Single-Site Study in China of ThermoDox® Plus RFA in the Journal of Cancer Research and Therapeutics
27 août 2019 08h00 HE
|
Celsion CORP
Data show overall survival improvement of 22.5 months with ThermoDox® plus RFA of 45 minutes or longer Data provides additional corroboration of ThermoDox’s potential for superior efficacy when...
Celsion Announces IRB Approval to Begin a Clinical Study of ThermoDox® Plus High Intensity Focused Ultrasound in Breast Cancer Patients at University Medical Center Utrecht in the Netherlands
20 juin 2019 08h30 HE
|
Celsion CORP
An Investigator-Sponsored Phase I Safety and Feasibility Study Estimated to Begin Enrollment in the Second Half of 2019 The Study Further Reinforces the Broad Potential of ThermoDox to Treat a Range...